RNS Number : 8714N

Omega Diagnostics Group PLC

06 June 2022

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.


("Omega" or the "Company" or the "Group")

Result of General Meeting


Total Voting Rights

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces, further to the announcement of 6 May 2022, the passing of the Resolution at the General Meeting held earlier today. The Subscription and Open Offer remain conditional on Admission of the New Ordinary Shares to AIM which is expected to take place at 8.00 a.m. Wednesday 8 June 2022.

Voting details

The vote for the Resolution was carried out as a poll on the basis of proxies received and the votes of those present (11,815,745 for and 1,179,038 against, with 82,576 votes withheld), and on the basis of such poll it was resolved that the Resolution as contained in the Notice be passed as a Special Resolution.

Total Voting Rights

With effect from Admission the Company will have 237,685,180 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 13 May 2022.


 Omega Diagnostics Group PLC                                            www.omegadx.com 
 Jag Grewal, Chief Executive Officer                                    via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 finnCap Ltd                                                         Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore (Corporate 
 Alice Lane/ Harriet Ward (ECM) 
 Walbrook PR Limited                         Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                        Mob: 07980 541 893 
 Lianne Applegarth                                                   Mob: 07584 391 303 
 Sam Allen                                                           Mob: 07502 558 258 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

June 06, 2022 09:29 ET (13:29 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Omega Diagnostics Charts.